ARQ 501 in Subjects With Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00075933
Recruitment Status : Completed
First Posted : January 13, 2004
Last Update Posted : April 28, 2009
Information provided by:

Brief Summary:

ARQ 501, an investigational anticancer drug, is intended to selectively kill cancer cells and spare normal cells by restoring and activating cellular checkpoints known to be defective in cancer using the Company's unique biology platform, Activated Checkpoint Therapy™ (ACT).

ARQ 501 has the potential for improved activity and reduced toxicity over other molecular approaches and traditional cancer chemotherapy.

Condition or disease Intervention/treatment Phase
Cancer Drug: ARQ 501 Phase 1

Study Type : Interventional  (Clinical Trial)
Enrollment : 80 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Clinical, Pharmacokinetic Study of ARQ 501 in Subjects With Advanced Solid Tumors
Study Start Date : September 2003
Actual Primary Completion Date : January 2007
Actual Study Completion Date : January 2007

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Histologically or cytologically confirmed solid tumor that is metastatic, unresectable or recurrent and for which standard curative or palliative measures do not exist or are no longer effective.
  • ECOG performance status greater than or equal to 1
  • Life expectancy greater than three months
  • Acceptable pretreatment clinical laboratory results

Exclusion Criteria

  • Subjects who have had chemotherapy or radiotherapy within 4 weeks
  • Subjects receiving any other investigational agents
  • Subjects with known untreated brain metastases
  • Subjects receiving hepatic enzyme-inducing antiseizure drugs ("EIASD")
  • Subjects with uncontrolled intercurrent illnesses
  • Pregnant women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00075933

United States, Massachusetts
Dana Farber/Partners CancerCare Inc
Boston, Massachusetts, United States, 02115
United States, Texas
Mary Crowley Medical Research Center
Dallas, Texas, United States, 75201
Sponsors and Collaborators
Principal Investigator: Geoffrey I Shapiro, MD Dana-Farber Cancer Institute
Principal Investigator: C. Casey Cunningham, MD Mary Crowley Medical Research Center Identifier: NCT00075933     History of Changes
Other Study ID Numbers: ARQ 501-101
First Posted: January 13, 2004    Key Record Dates
Last Update Posted: April 28, 2009
Last Verified: April 2009

Additional relevant MeSH terms:
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Antiviral Agents